Impact of denosumab on bone mass in cancer patients

Ursa Brown-Glaberman, Alison T Stopeck

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Cancer therapy-induced bone loss (CTIBL) is a form of secondary osteoporosis associated with systemic chemotherapy and hormonal ablation therapy. The monitoring and treatment of CTIBL is an important component of comprehensive cancer care, especially for patients with curable disease and long life expectancies. Whereas oral bisphosphonates remain the most commonly used therapeutic option for CTIBL, additional treatment options may be required for patients who do not respond adequately or are intolerant to bisphosphonates, have renal insufficiency, or are receiving treatment with nephrotoxic medications. For these patients, denosumab, a monoclonal antibody targeting the receptor activator of nuclear factor-κB ligand (RANKL), offers an effective and well-tolerated alternative. Several recent randomized trials have examined the use of denosumab as treatment for CTIBL associated with hormone ablation therapy for breast and prostate cancer. Recent data suggest a possible role for RANKL inhibitors in both chemoprevention and the prevention of cancer recurrence through direct effects on breast tissue and breast cancer stem cells. The outcomes of several international Phase III clinical trials currently underway will help clarify the role of denosumab in patients undergoing cancer therapy.

Original languageEnglish (US)
Pages (from-to)117-129
Number of pages13
JournalClinical Pharmacology: Advances and Applications
Volume5
DOIs
StatePublished - 2013

Fingerprint

Bone and Bones
Neoplasms
Therapeutics
Diphosphonates
Denosumab
Breast Neoplasms
Phase III Clinical Trials
Neoplastic Stem Cells
Chemoprevention
Cytoplasmic and Nuclear Receptors
Life Expectancy
Osteoporosis
Renal Insufficiency
Prostatic Neoplasms
Patient Care
Breast
Monoclonal Antibodies
Hormones
Ligands
Recurrence

Keywords

  • Cancer therapy-induced bone loss
  • Chemotherapy
  • Denosumab
  • Hormone ablation therapy
  • Osteopenia
  • Osteoporosis

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Impact of denosumab on bone mass in cancer patients. / Brown-Glaberman, Ursa; Stopeck, Alison T.

In: Clinical Pharmacology: Advances and Applications, Vol. 5, 2013, p. 117-129.

Research output: Contribution to journalArticle

@article{6d0970e667dd45959615b422262e3d5c,
title = "Impact of denosumab on bone mass in cancer patients",
abstract = "Cancer therapy-induced bone loss (CTIBL) is a form of secondary osteoporosis associated with systemic chemotherapy and hormonal ablation therapy. The monitoring and treatment of CTIBL is an important component of comprehensive cancer care, especially for patients with curable disease and long life expectancies. Whereas oral bisphosphonates remain the most commonly used therapeutic option for CTIBL, additional treatment options may be required for patients who do not respond adequately or are intolerant to bisphosphonates, have renal insufficiency, or are receiving treatment with nephrotoxic medications. For these patients, denosumab, a monoclonal antibody targeting the receptor activator of nuclear factor-κB ligand (RANKL), offers an effective and well-tolerated alternative. Several recent randomized trials have examined the use of denosumab as treatment for CTIBL associated with hormone ablation therapy for breast and prostate cancer. Recent data suggest a possible role for RANKL inhibitors in both chemoprevention and the prevention of cancer recurrence through direct effects on breast tissue and breast cancer stem cells. The outcomes of several international Phase III clinical trials currently underway will help clarify the role of denosumab in patients undergoing cancer therapy.",
keywords = "Cancer therapy-induced bone loss, Chemotherapy, Denosumab, Hormone ablation therapy, Osteopenia, Osteoporosis",
author = "Ursa Brown-Glaberman and Stopeck, {Alison T}",
year = "2013",
doi = "10.2147/CPAA.S30330",
language = "English (US)",
volume = "5",
pages = "117--129",
journal = "Clinical Pharmacology: Advances and Applications",
issn = "1179-1438",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Impact of denosumab on bone mass in cancer patients

AU - Brown-Glaberman, Ursa

AU - Stopeck, Alison T

PY - 2013

Y1 - 2013

N2 - Cancer therapy-induced bone loss (CTIBL) is a form of secondary osteoporosis associated with systemic chemotherapy and hormonal ablation therapy. The monitoring and treatment of CTIBL is an important component of comprehensive cancer care, especially for patients with curable disease and long life expectancies. Whereas oral bisphosphonates remain the most commonly used therapeutic option for CTIBL, additional treatment options may be required for patients who do not respond adequately or are intolerant to bisphosphonates, have renal insufficiency, or are receiving treatment with nephrotoxic medications. For these patients, denosumab, a monoclonal antibody targeting the receptor activator of nuclear factor-κB ligand (RANKL), offers an effective and well-tolerated alternative. Several recent randomized trials have examined the use of denosumab as treatment for CTIBL associated with hormone ablation therapy for breast and prostate cancer. Recent data suggest a possible role for RANKL inhibitors in both chemoprevention and the prevention of cancer recurrence through direct effects on breast tissue and breast cancer stem cells. The outcomes of several international Phase III clinical trials currently underway will help clarify the role of denosumab in patients undergoing cancer therapy.

AB - Cancer therapy-induced bone loss (CTIBL) is a form of secondary osteoporosis associated with systemic chemotherapy and hormonal ablation therapy. The monitoring and treatment of CTIBL is an important component of comprehensive cancer care, especially for patients with curable disease and long life expectancies. Whereas oral bisphosphonates remain the most commonly used therapeutic option for CTIBL, additional treatment options may be required for patients who do not respond adequately or are intolerant to bisphosphonates, have renal insufficiency, or are receiving treatment with nephrotoxic medications. For these patients, denosumab, a monoclonal antibody targeting the receptor activator of nuclear factor-κB ligand (RANKL), offers an effective and well-tolerated alternative. Several recent randomized trials have examined the use of denosumab as treatment for CTIBL associated with hormone ablation therapy for breast and prostate cancer. Recent data suggest a possible role for RANKL inhibitors in both chemoprevention and the prevention of cancer recurrence through direct effects on breast tissue and breast cancer stem cells. The outcomes of several international Phase III clinical trials currently underway will help clarify the role of denosumab in patients undergoing cancer therapy.

KW - Cancer therapy-induced bone loss

KW - Chemotherapy

KW - Denosumab

KW - Hormone ablation therapy

KW - Osteopenia

KW - Osteoporosis

UR - http://www.scopus.com/inward/record.url?scp=84879809231&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879809231&partnerID=8YFLogxK

U2 - 10.2147/CPAA.S30330

DO - 10.2147/CPAA.S30330

M3 - Article

C2 - 23861604

AN - SCOPUS:84879809231

VL - 5

SP - 117

EP - 129

JO - Clinical Pharmacology: Advances and Applications

JF - Clinical Pharmacology: Advances and Applications

SN - 1179-1438

ER -